Matches in Wikidata for { <http://www.wikidata.org/entity/Q86693370> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q86693370 description "artículu científicu espublizáu en xineru de 2015" @default.
- Q86693370 description "scientific article published on 23 January 2015" @default.
- Q86693370 description "wetenschappelijk artikel" @default.
- Q86693370 description "наукова стаття, опублікована в січні 2015" @default.
- Q86693370 name "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 name "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 type Item @default.
- Q86693370 label "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 label "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 prefLabel "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 prefLabel "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous" @default.
- Q86693370 P1433 Q86693370-1F97287B-A81A-4629-B395-69CD23968C30 @default.
- Q86693370 P1476 Q86693370-44452689-3EB4-41BD-A3C2-7F07838983CA @default.
- Q86693370 P2093 Q86693370-055A03C4-FAB8-419C-BAE7-B233AB5DA49E @default.
- Q86693370 P2093 Q86693370-0AA613F4-771A-4C5D-9986-4A00E627C845 @default.
- Q86693370 P2093 Q86693370-0C40D9EC-B270-4214-9CBD-DE43ACC7662A @default.
- Q86693370 P2093 Q86693370-1B60D52A-E64A-4BFA-A16F-0627FFB965DC @default.
- Q86693370 P2093 Q86693370-2DBF10C7-B9B2-4E98-AEB7-F0FC5CF29E1F @default.
- Q86693370 P2093 Q86693370-36264059-0640-4F69-AAF1-3E686559AE8F @default.
- Q86693370 P2093 Q86693370-44631DF4-FE01-4915-8C0E-621163DD1B50 @default.
- Q86693370 P2093 Q86693370-564B78F2-A99A-40AE-8F23-5FAFFCA17B0D @default.
- Q86693370 P2093 Q86693370-58FBA195-7D04-4260-9BCE-E47869360D6C @default.
- Q86693370 P2093 Q86693370-6115D9BF-CDC2-45DC-ACC9-434F91FB08B6 @default.
- Q86693370 P2093 Q86693370-638D5395-EFC4-46A3-B9DC-5BFC72748359 @default.
- Q86693370 P2093 Q86693370-68662F01-B349-4478-9AAD-AEA715B10C60 @default.
- Q86693370 P2093 Q86693370-ABF50AF9-9F04-4D12-891F-2D5E3A1705B7 @default.
- Q86693370 P2093 Q86693370-B8508BD3-920F-4F21-BDE2-A5962C934ED2 @default.
- Q86693370 P2093 Q86693370-E0DCE469-5ADF-435A-A294-4ADB6922563B @default.
- Q86693370 P2093 Q86693370-EB7478A3-31DE-4CB4-88DD-0D39AAAB52D5 @default.
- Q86693370 P2093 Q86693370-FF590677-F783-4505-B32C-AEE5EA7F0A26 @default.
- Q86693370 P304 Q86693370-E6D5BF6E-1A37-4B56-AD25-44452F21D2F6 @default.
- Q86693370 P31 Q86693370-C1AB71D3-B405-4A1D-B588-CFBC5690732D @default.
- Q86693370 P356 Q86693370-CC05D0D5-27EC-4D99-8F70-E28924716B05 @default.
- Q86693370 P433 Q86693370-7C066574-6538-4DD0-9275-14A0C0895096 @default.
- Q86693370 P478 Q86693370-4BDF3B33-E07C-4AC2-8735-5610629433EF @default.
- Q86693370 P577 Q86693370-B8672244-02C1-42F8-B2DA-B5B2DD3A6DDC @default.
- Q86693370 P698 Q86693370-78A5F925-4DA7-4035-BD0C-7E3CBC0E9B30 @default.
- Q86693370 P921 Q86693370-1B1B9EED-4D39-4CDB-AFBC-F15BD0EBCA7B @default.
- Q86693370 P921 Q86693370-CC1DD469-516F-43EB-93D1-9E3460F2EABE @default.
- Q86693370 P921 Q86693370-CF52B1EB-630F-462A-9320-DA2B59A2B4A2 @default.
- Q86693370 P356 J.LUNGCAN.2015.01.012 @default.
- Q86693370 P698 25662596 @default.
- Q86693370 P1433 Q641464 @default.
- Q86693370 P1476 "Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG)" @default.
- Q86693370 P2093 "A Agelidou" @default.
- Q86693370 P2093 "A Kotsakis" @default.
- Q86693370 P2093 "A Polyzos" @default.
- Q86693370 P2093 "Ch Emmanouilidis" @default.
- Q86693370 P2093 "D Hatzidaki" @default.
- Q86693370 P2093 "D Mavroudis" @default.
- Q86693370 P2093 "D Stoltidis" @default.
- Q86693370 P2093 "E K Vetsika" @default.
- Q86693370 P2093 "G Nintos" @default.
- Q86693370 P2093 "K Kalbakis" @default.
- Q86693370 P2093 "L Vamvakas" @default.
- Q86693370 P2093 "M Vaslamatzis" @default.
- Q86693370 P2093 "N Kentepozidis" @default.
- Q86693370 P2093 "P Katsaounis" @default.
- Q86693370 P2093 "S Agelaki" @default.
- Q86693370 P2093 "V Chandrinos" @default.
- Q86693370 P2093 "V Georgoulias" @default.
- Q86693370 P304 "57-62" @default.
- Q86693370 P31 Q13442814 @default.
- Q86693370 P356 "10.1016/J.LUNGCAN.2015.01.012" @default.
- Q86693370 P433 "1" @default.
- Q86693370 P478 "88" @default.
- Q86693370 P577 "2015-01-23T00:00:00Z" @default.
- Q86693370 P698 "25662596" @default.
- Q86693370 P921 Q412415 @default.
- Q86693370 P921 Q413299 @default.
- Q86693370 P921 Q420436 @default.